Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal Cancer: The Canadian Cancer Trials Group CO.26 Study.

MLA

Chen, Eric X., et al. “Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal Cancer: The Canadian Cancer Trials Group CO.26 Study.” JAMA Oncology, vol. 6, no. 6, June 2020, pp. 831–38. EBSCOhost, https://doi.org/10.1001/jamaoncol.2020.0910.

APA

Chen, E. X., Jonker, D. J., Loree, J. M., Kennecke, H. F., Berry, S. R., Couture, F., Ahmad, C. E., Goffin, J. R., Kavan, P., Harb, M., Colwell, B., Samimi, S., Samson, B., Abbas, T., Aucoin, N., Aubin, F., Koski, S. L., Wei, A. C., Magoski, N. M., … O’Callaghan, C. J. (2020). Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal Cancer: The Canadian Cancer Trials Group CO.26 Study. JAMA Oncology, 6(6), 831–838. https://doi.org/10.1001/jamaoncol.2020.0910

Chicago

Chen, Eric X, Derek J Jonker, Jonathan M Loree, Hagen F Kennecke, Scott R Berry, Felix Couture, Chaudhary E Ahmad, et al. 2020. “Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal Cancer: The Canadian Cancer Trials Group CO.26 Study.” JAMA Oncology 6 (6): 831–38. doi:10.1001/jamaoncol.2020.0910.